Companies: 10,795·Total market cap: $144.5T
CuraScientific Corp

CuraScientific Corp

CSTFOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$377345
P/E Ratio
52W High$0.0001
52W Low$0.0001
Overview

CuraScientific Corp (CSTF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CSTF · free cash flow · updated Jun 9, 2026

Core FCF metrics

Free cash flow was −$268,624 for FY2022 (fiscal year ending 2022-12-31), up 52.0% year-over-year The FCF margin was -780.1%.

FY2022 Free Cash Flow−$268,624▲ +52.0% YoY
Trailing 12M (TTM)−$401,988trailing 4 quarters sum
FCF Margin-780.1%−$268,624 ÷ revenue
3-Year CAGRN/AN/A — contains negative FCF
5-Year CAGRN/AN/A — contains negative FCF
FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

Positive FCFNegative FCF
Free Cash Flow
YoY Growth %
cstf free cash flow history · cstf free cash flow chart · cstf free cash flow growth rate · cstf free cash flow last 10 years

Annual free cash flow data

Fiscal YearFree Cash FlowYoY ChangeFCF Margin
FY2022Latest−$268,624▲ +52.0%-780.1%
FY2021−$559,386▼ 29.1%-648.5%
FY2020−$433,389▼ 33489.0%-720.4%
FY2019$1,298▼ 88.9%1.6%
FY2018$11,704▲ +148.0%13.7%
FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP
cstf free cash flow 2022 · cstf free cash flow 2021 · cstf free cash flow 2020 · cstf operating cash flow

FCF valuation metrics

CuraScientific Corp (CSTF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)
N/A
Free Cash Flow ÷ Market Cap
per FMP freeCashFlowYieldTTM definition
FCF per Share (TTM)
N/A
TTM FCF ÷ Shares Outstanding
Price / FCF
N/A
Share Price ÷ FCF per Share
EV / FCF (TTM)
N/A
Enterprise Value basis
!

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31
cstf price to free cash flow · cstf free cash flow yield · cstf free cash flow per share · cstf price to cash flow ratio

Cash flow statement summary

For FY2022, CuraScientific Corp generated −$0.3M in operating cash flow and spent 0M in capital expenditures, yielding −$0.3M in free cash flow.

Operating Activities
−$0.3M
Cash from core business operations
2022-12-31
Investing Activities
−$0.0M
CapEx, acquisitions & investments
2022-12-31
Financing Activities
+$0.2M
Buybacks, dividends & debt
2022-12-31
FCF FormulaOperating CF (−$0.3M) − |CapEx| (0M) = FCF (−$0.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement
cstf cash flow statement · cstf cash flow statement 2022 · cstf operating cash flow · cstf cash flow from operations

Free cash flow vs peers (Healthcare)

#CompanyFree Cash FlowYoY
#1
CuraScientific Corp
CuraScientific CorpYOU
CSTF
−$268,624+52.0%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$19.70B-0.7%
#3
AbbVie Inc.
AbbVie Inc.
ABBV
$17.82B-0.1%
#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$16.07B-22.4%
#5
Eli Lilly and Company
Eli Lilly and Company
LLY
$8.97B+2065.6%
Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

CuraScientific Corp (CSTF) reported free cash flow of −$268,624 for FY2022 (fiscal year ending 2022-12-31), up 52.0% year-over-year. The FCF margin was -780.1%.

Based on available data, CuraScientific Corp has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $11,704 in FY2018.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Frequently asked questions

CSTF free cash flow · 8 questions

CuraScientific Corp free cash flow was −$268,624 for FY2022, up 52.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$401,988.

CSTF free cash flowCSTF FCFCSTF FCF 2022CSTF free cash flow TTM

Source: FMP /cash-flow-statement · US GAAP · CuraScientific Corp · CuraScientific Corp SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026